Tag: KD025-213

Home / KD025-213

Categories

The FDA has approved belumosudil for the treatment of chronic graft-versus-host disease

August 2021: After failure of at least two prior lines of systemic therapy, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult...
kd025-213

Scan the code